A study aimed to clarify the relationship between anxiety and depression in patients with multiple sclerosis.
Mindfulness meditation was associated with improvements in measures of anxiety, depression, and negative thoughts.
Opicinumab may potentially enhance spontaneous remyelination after acute optic neuritis.
Emflaza is approved for the treatment of Duchenne muscular dystrophy regardless of genetic etiology.
Several new multiple sclerosis drugs, including natalizumab, may be more effective at reducing relapses but still come with serious safety concerns.
Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.
Several microRNA were found to be associated with lesion volume and brain atrophy in multiple sclerosis.
Despite an elevated risk of PML, treatment with natalizumab results in slower disease progression than other treatments.
Patients with both MS and epileptic seizures had a younger age at onset of MS compared with those without seizures.
Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.
Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
More structured MRI reports may aid in the diagnosis of multiple sclerosis.
It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.
The US FDA has approved the first drug for the treatment of spinal muscular atrophy, a genetic disease that often results in premature death.
Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.
Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.
Despite the benefits observed, the improvements still do not represent normal muscle function.
Patients with cancer or an autoimmune disease who underwent surgery were at a greater risk.
Sixty-three percent of patients achieved a complete and stable response that allowed them to discontinue all immunotherapies.
Previous MRI studies focused on gray matter changes only.
The foods most negatively correlated with ALSFRS-R score were milk, lunchmeats, and beef and pork.
The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.
Researchers still recommend that patients with MS engage in physical activity for cardiovascular benefits.
Researchers believe that the drug may help prevent MS, since there was a 96% reduction in harmful clusters of B cells.
Eteplirsen is the first drug approved in the US for the treatment of DMD.
Notably, patients who had documented psychotic and psychiatric disorders were more likely to be diagnosed with a demyelinating disease.
Over 90% of participants achieved NEDA-3 after being transitioned to dimethyl-fumarate from natalizumab.
The relationship between microstructural damage in NAWM and clinical measures was less clear, suggesting another mechanism.
Researchers examined whether the cognitive reserve hypothesis could predict cognitive decline, gray matter volume changes, and white matter volume changes in MS patients.
High-fat diets may increase the risk of relapse in children with MS, while high-vegetable diets may be protective.
Neurology Advisor Articles
- New Sleep Apnea Clinical Practice Guidelines
- International League Against Epilepsy Updates Epilepsy Classification System
- In Refractory Status Epilepticus, Lacosamide May Be a Good Option
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- The Handoff: Your Week in Neurology News - 3/23/17
- Q&A: Strategies for Transitioning Pediatric Patients to Adult Care
- Epilepsy Risk May Increase After Incident Depression
- Alzheimer's Caregiver Coping Program Does Not Increase Health Care Costs
- Valproate for Epilepsy Poses Greater Risk for Major Congenital Malformations
- VTE Recurrence Decreased With Rivaroxaban